bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S6 from Tumor Cell–Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer
Authors: Singh Samara P. , Dosch Austin R. , Mehra Siddharth , De Castro Silva Iago , Bianchi Anna , Garrido Vanessa T. , Zhou Zhiqun , Adams Andrew , Amirian Haleh , Box Edmond W. , Sun Xiaodian , Ban Yuguang , Datta Jashodeep , Nagathihalli Nagaraj S. , Merchant Nipun B.
Published: April 2024

Supplementary data for flow cytometry gating
Supplementary Figure S5 from Tumor Cell–Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer
Authors: Singh Samara P. , Dosch Austin R. , Mehra Siddharth , De Castro Silva Iago , Bianchi Anna , Garrido Vanessa T. , Zhou Zhiqun , Adams Andrew , Amirian Haleh , Box Edmond W. , Sun Xiaodian , Ban Yuguang , Datta Jashodeep , Nagathihalli Nagaraj S. , Merchant Nipun B.
Published: April 2024

Supplementary Data for figure 3 and 4.
Figure S1 from Fibroblasts in the Aged Pancreas Drive Pancreatic Cancer Progression
Authors: Zabransky Daniel J. , Chhabra Yash , Fane Mitchell E. , Kartalia Emma , Leatherman James M. , Hüser Laura , Zimmerman Jacquelyn W. , Delitto Daniel , Han Song , Armstrong Todd D. , Charmsaz Soren , Guinn Samantha , Pramod Sneha , Thompson Elizabeth D. , Hughes Steven J. , O'Connell Jennifer , Egan Josephine M. , Jaffee Elizabeth M. , Weeraratna Ashani T.
Published: April 2024

Figure S1
Data from Tumor Cell–Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer
Authors: Singh Samara P. , Dosch Austin R. , Mehra Siddharth , De Castro Silva Iago , Bianchi Anna , Garrido Vanessa T. , Zhou Zhiqun , Adams Andrew , Amirian Haleh , Box Edmond W. , Sun Xiaodian , Ban Yuguang , Datta Jashodeep , Nagathihalli Nagaraj S. , Merchant Nipun B.
Published: April 2024

Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a KRAS-driven inflammatory program and a desmoplastic stroma, which contribute to the profoundly chemoresistant phenotype. The tumor stroma contains an abundance of cancer-associated fibroblasts (CAF), which engage in extensive paracrine cross-talk with tumor cells to perpetuate protumorigenic inflammation. IL1α, a pleiotropic, tumor cell–derived cytokine, plays a critical role in shaping the stromal landscape. To provide insights into the molecular mechanisms regulating IL1A expression in PDAC, we performed transcriptional profiling of The Cancer Genome Atlas datasets and pharmacologic screening in PDAC cells and identified p38α MAPK as a key positive regulator of IL1A expression. Both genetic and pharmacologic inhibition of p38 MAPK significantly diminished IL1α production in vitro. Chromatin- and coimmunoprecipitation analyses revealed that p38 MAPK coordinates the transcription factors Sp1 and the p65 subunit of NFκB to drive IL1A overexpression. Single-cell RNA sequencing of a highly desmoplastic murine PDAC model, Ptf1aCre/+; LSL-KrasG12D/+; Tgfbr2flox/flox (PKT), confirmed that p38 MAPK inhibition significantly decreases tumor cell–derived Il1a and attenuates the inflammatory CAF phenotype in a paracrine IL1α-dependent manner. Furthermore, p38 MAPK inhibition favorably modulated intratumoral immunosuppressive myeloid populations and augmented chemotherapeutic efficacy to substantially reduce tumor burden and improve overall survival in PKT mice. These findings illustrate a cellular mechanism of tumor cell–intrinsic p38-p65/Sp1-IL1α signaling that is responsible for sustaining stromal inflammation and CAF activation, offering an attractive therapeutic approach to enhance chemosensitivity in PDAC.
Significance:
Inhibition of p38 MAPK suppresses tumor cell–derived IL1α and attenuates the inflammatory stroma and immunosuppressive tumor microenvironment to overcome chemotherapeutic resistance in pancreatic cancer.
Data from The Web-Based Portal SpatialTME Integrates Histological Images with Single-Cell and Spatial Transcriptomics to Explore the Tumor Microenvironment
Authors: Shi Jintong , Wei Xia , Xun Zhenzhen , Ding Xinyu , Liu Yao , Liu Lianxin , Ye Youqiong
Published: April 2024

Abstract
The tumor microenvironment (TME) represents a complex network in which tumor cells communicate not only with each other but also with stromal and immune cells. The intercellular interactions in the TME contribute to tumor initiation, progression, metastasis, and treatment outcome. Recent advances in spatial transcriptomics (ST) have revolutionized the molecular understanding of the TME at the spatial level. A comprehensive interactive analysis resource specifically designed for characterizing the spatial TME could facilitate further advances using ST. In this study, we collected 296 ST slides covering 19 cancer types and developed a computational pipeline to delineate the spatial structure along the malignant–boundary–nonmalignant axis. The pipeline identified differentially expressed genes and their functional enrichment, deconvoluted the cellular composition of the TME, reconstructed cell type–specific gene expression profiles at the sub-spot level, and performed cell–cell interaction analysis. Finally, the user-friendly database SpatialTME (http://www.spatialtme.yelab.site/) was constructed to provide search, visualization, and downloadable results. These detailed analyses are able to reveal the heterogeneous regulatory network of the spatial microenvironment and elucidate associations between spatial features and tumor development or response to therapy, offering a valuable resource to study the complex TME.
Significance:
SpatialTME provides spatial structure, cellular composition, expression, function, and cell–cell interaction information to enable investigations into the tumor microenvironment at the spatial level to advance understanding of cancer development and treatment.
Data from TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Cordova Ricardo A. , Rupert Christopher , Delle Fontane Ilaria , Shen Li , Orsi Sabrina , Klunk Angela J. , Linehan W. Marston , Staschke Kirk A. , Hollenhorst Peter C. , Heppner David E. , Pili Roberto
Published: April 2024

Abstract
TFE3 is a member of the basic helix–loop–helix leucine zipper MiT transcription factor family, and its chimeric proteins are associated with translocation renal cell carcinoma (tRCC). Despite the variety of gene fusions, most TFE3 fusion partner genes are related to spliceosome machinery. Dissecting the function of TFE3 fused to spliceosome machinery factors (TFE3-SF) could direct the development of effective therapies for this lethal disease, which is refractory to standard treatments for kidney cancer. Here, by using a combination of in silico structure prediction, transcriptome profiling, molecular characterization, and high-throughput high-content screening (HTHCS), we interrogated a number of oncogenic mechanisms of TFE3-SF fusions. TFE3-SF fusions drove the transformation of kidney cells and promoted distinct oncogenic phenotypes in a fusion partner-dependent manner, differentially altering the transcriptome and RNA splicing landscape and activating different oncogenic pathways. Inhibiting TFE3-SF dimerization reversed its oncogenic activity and represented a potential target for therapeutic intervention. Screening the FDA-approved drugs library LOPAC and a small-molecule library (Microsource) using HTHCS combined with FRET technology identified compounds that inhibit TFE3-SF dimerization. Hit compounds were validated in 2D and 3D patient-derived xenograft models expressing TFE3-SF. The antihistamine terfenadine decreased cell proliferation and reduced in vivo tumor growth of tRCC. Overall, these results unmask therapeutic strategies to target TFE3-SF dimerization for treating patients with tRCC.
Significance:
TFE3-splicing factor fusions possess both transcription and splicing factor functions that remodel the transcriptome and spliceosome and can be targeted with dimerization inhibitors to suppress the growth of translocation renal cell carcinoma.
Data from Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
Authors: Zhu Xianbing , Fu Zheng , Dutchak Kendall , Arabzadeh Azadeh , Milette Simon , Steinberger Jutta , Morin Geneviève , Monast Anie , Pilon Virginie , Kong Tim , Adams Bianca N. , Prando Munhoz Erika , Hosein Hannah J.B. , Fang Tianxu , Su Jing , Xue Yibo , Rayes Roni , Sangwan Veena , Walsh Logan A. , Chen Guojun , Quail Daniela F. , Spicer Jonathan D. , Park Morag , Dankort David , Huang Sidong
Published: April 2024

Abstract
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including KRAS-mutant non–small cell lung cancer (NSCLC). However, the clinical efficacy of CDK4/6 inhibitors is limited due to frequent drug resistance and their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred resistance to the CDK4/6 inhibitor palbociclib in KRAS-mutant NSCLC cells. Inhibition of BRD4, either by RNA interference or small-molecule inhibitors, synergized with palbociclib to induce senescence in NSCLC cells and tumors, and the combination prolonged survival in a KRAS-mutant NSCLC mouse model. Mechanistically, BRD4-inhibition enhanced cell-cycle arrest and reactive oxygen species (ROS) accumulation, both of which are necessary for senescence induction; this in turn elevated GPX4, a peroxidase that suppresses ROS-triggered ferroptosis. Consequently, GPX4 inhibitor treatment selectively induced ferroptotic cell death in the senescent cancer cells, resulting in tumor regression. Cotargeting CDK4/6 and BRD4 also promoted senescence and ferroptosis vulnerability in pancreatic and breast cancer cells. Together, these findings reveal therapeutic vulnerabilities and effective combinations to enhance the clinical utility of CDK4/6 inhibitors.
Significance:
The combination of cytostatic CDK4/6 and BRD4 inhibitors induces senescent cancer cells that are primed for activation of ferroptotic cell death by targeting GPX4, providing an effective strategy for treating cancer.
Data from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression
Authors: Chen Yongheng , Ying Ying , Ma Wenlong , Ma Hongchao , Shi Liang , Gao Xuefeng , Jia Min , Li Meiqi , Song Xiaoman , Kong Weixiao , Chen Wei , Zheng Xiangyi , Muluh Tobias Achu , Wang Xiaobin , Wang Maolin , Shu Xing-sheng
Published: April 2024

Abstract
Epigenetic alterations at cis-regulatory elements (CRE) fine-tune transcriptional output. Epigenetic readers interact with CREs and can cooperate with other chromatin regulators to drive oncogene transcription. Here, we found that the YEATS domain-containing histone acetylation reader ENL (eleven–nineteen leukemia) acts as a key regulator of super-enhancers (SE), which are highly active distal CREs, across cancer types. ENL occupied the majority of SEs with substantially higher preference over typical enhancers, and the enrichment of ENL at SEs depended on its ability to bind acetylated histones. Rapid depletion of ENL by auxin-inducible degron tagging severely repressed the transcription of SE-controlled oncogenes, such as MYC, by inducing the decommissioning of their SEs, and restoring ENL protein expression largely reversed these effects. Additionally, ENL was indispensable for the rapid activation of SE-regulated immediate early genes in response to growth factor stimulation. Furthermore, ENL interacted with the histone chaperone FACT complex and was required for the deposition of FACT over CREs, which mediates nucleosome reorganization required for transcription initiation and elongation. Proper control of transcription by ENL and ENL-associated FACT was regulated by the histone reader BRD4. ENL was overexpressed in colorectal cancer and functionally contributed to colorectal cancer growth and metastasis. ENL degradation or inhibition synergized with BET inhibitors that target BRD4 in restraining colorectal cancer progression. These findings establish the essential role of epigenetic reader ENL in governing SE-driven oncogenic transcription and uncover the potential of ENL intervention to increase sensitivity to BET inhibition.
Significance:
ENL plays a key role in decoding epigenetic marks at highly active oncogenic super-enhancers and can be targeted in combination with BET inhibition as a promising synergistic strategy for optimizing cancer treatment.
Supplemental Table 3 from ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature
Authors: Vellky Jordan E. , Kirkpatrick Brenna J. , Gutgesell Lisa C. , Morales Mathias , Brown Ryan M. , Wu Yaqi , Maienschein-Cline Mark , Notardonato Lucia D. , Weinfeld Michael S. , Nguyen Ryan H. , Brister Eileen , Sverdlov Maria , Liu Li , Xu Ziqiao , Kregel Steven , Nonn Larisa , Vander Griend Donald J. , Reizine Natalie M.
Published: April 2024

Supplemental Table 3. Antibody Specifications.
Supplemental Figure 3 from ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature
Authors: Vellky Jordan E. , Kirkpatrick Brenna J. , Gutgesell Lisa C. , Morales Mathias , Brown Ryan M. , Wu Yaqi , Maienschein-Cline Mark , Notardonato Lucia D. , Weinfeld Michael S. , Nguyen Ryan H. , Brister Eileen , Sverdlov Maria , Liu Li , Xu Ziqiao , Kregel Steven , Nonn Larisa , Vander Griend Donald J. , Reizine Natalie M.
Published: April 2024

Supplemental Figure 3: ERBB3 Expression and Preliminary Clinical Outcomes.
Supplemental Figure 2 from ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature
Authors: Vellky Jordan E. , Kirkpatrick Brenna J. , Gutgesell Lisa C. , Morales Mathias , Brown Ryan M. , Wu Yaqi , Maienschein-Cline Mark , Notardonato Lucia D. , Weinfeld Michael S. , Nguyen Ryan H. , Brister Eileen , Sverdlov Maria , Liu Li , Xu Ziqiao , Kregel Steven , Nonn Larisa , Vander Griend Donald J. , Reizine Natalie M.
Published: April 2024

Supplemental Figure 2: HER3 Gain-of-function in Additional Models.
Supplemental Figure 1 from ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature
Authors: Vellky Jordan E. , Kirkpatrick Brenna J. , Gutgesell Lisa C. , Morales Mathias , Brown Ryan M. , Wu Yaqi , Maienschein-Cline Mark , Notardonato Lucia D. , Weinfeld Michael S. , Nguyen Ryan H. , Brister Eileen , Sverdlov Maria , Liu Li , Xu Ziqiao , Kregel Steven , Nonn Larisa , Vander Griend Donald J. , Reizine Natalie M.
Published: April 2024

Supplemental Figure 1: ERBB3 Expression between Patient Datasets and Kinase Family Member Expression in ERBB3 High vs. Low.
Supplementary Table 2 from Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
Authors: Lee Eun Ji , Oh Seung Yeon , Lee You Won , Kim Ju Young , Kim Min-Je , Kim Tae Ho , Lee Jii Bum , Hong Min Hee , Lim Sun Min , Baum Anke , Woelflingseder Lydia , Engelhardt Harald , Petronczki Mark , Solca Flavio , Yun Mi Ran , Cho Byoung Chul
Published: April 2024

KINOMEscan selectivity profiling of BI-4732
Supplementary Table 1 from Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
Authors: Lee Eun Ji , Oh Seung Yeon , Lee You Won , Kim Ju Young , Kim Min-Je , Kim Tae Ho , Lee Jii Bum , Hong Min Hee , Lim Sun Min , Baum Anke , Woelflingseder Lydia , Engelhardt Harald , Petronczki Mark , Solca Flavio , Yun Mi Ran , Cho Byoung Chul
Published: April 2024

The EGFR mutation status of patient-derived models using whole exome sequencing analysis
Supplementary Figure S6 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Authors: Griesinger Andrea M. , Calzadilla Annaliese J. , Grimaldo Enrique , Donson Andrew M. , Amani Vladimir , Pierce Angela M. , Steiner Jenna , Kargar Soudabeh , Serkova Natalie J. , Bertrand Kelsey C. , Wright Karen D. , Vibhakar Rajeev , Hankinson Todd , Handler Michael , Lindsay Holly B. , Foreman Nicholas K. , Dorris Kathleen
Published: April 2024

MAF-928 in vivo mice had more metastatic lesions with radiation alone.
Supplementary Figure S3 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Authors: Griesinger Andrea M. , Calzadilla Annaliese J. , Grimaldo Enrique , Donson Andrew M. , Amani Vladimir , Pierce Angela M. , Steiner Jenna , Kargar Soudabeh , Serkova Natalie J. , Bertrand Kelsey C. , Wright Karen D. , Vibhakar Rajeev , Hankinson Todd , Handler Michael , Lindsay Holly B. , Foreman Nicholas K. , Dorris Kathleen
Published: April 2024

Densitometry for apoptosis proteomic array of 1q+ PFA cell lines treated with
5FU and 5Gy radiation.
Supplementary Table S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Authors: Bartlett John M.S. , Xu Keying , Wong Jenna , Pond Gregory , Zhang Yi , Spears Melanie , Salunga Ranelle , Mallon Elizabeth , Taylor Karen J. , Hasenburg Annette , Markopoulos Christos , Dirix Luc , van de Velde Cornelis J.H. , Rea Daniel , Schnabel Catherine A. , Treuner Kai , Bayani Jane
Published: April 2024

Supplemental Table 2. Distribution of patients as defined by BCI prognostic (BCI/BCIN+) and BCI predictive (BCI (H/I)).
Supplementary Table S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Authors: Bartlett John M.S. , Xu Keying , Wong Jenna , Pond Gregory , Zhang Yi , Spears Melanie , Salunga Ranelle , Mallon Elizabeth , Taylor Karen J. , Hasenburg Annette , Markopoulos Christos , Dirix Luc , van de Velde Cornelis J.H. , Rea Daniel , Schnabel Catherine A. , Treuner Kai , Bayani Jane
Published: April 2024

Supplemental Table 1. Prognostic performance of BCI and BCIN+ optimized cut-points for late DR in all patients with N0 and N1 breast cancers, as well as in HER2- subsets, respectively.
Supplementary Table S9 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Authors: Dorff Tanya , Horvath Lisa G. , Autio Karen , Bernard-Tessier Alice , Rettig Matthew B. , Machiels Jean-Pascal , Bilen Mehmet A. , Lolkema Martijn P. , Adra Nabil , Rottey Sylvie , Greil Richard , Matsubara Nobuaki , Tan Daniel S.W. , Wong Alvin , Uemura Hiroji , Lemech Charlotte , Meran Johannes , Yu Youfei , Minocha Mukul , McComb Mason , Penny Hweixian Leong , Gupta Vinita , Hu Xuguang , Jurida Gabor , Kouros-Mehr Hosein , Janát-Amsbury Margit M. , Eggert Tobias , Tran Ben
Published: April 2024

Radiographic progression-free survival in patients according to baseline tumor PSMA expression
Supplementary Figure S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Authors: Bartlett John M.S. , Xu Keying , Wong Jenna , Pond Gregory , Zhang Yi , Spears Melanie , Salunga Ranelle , Mallon Elizabeth , Taylor Karen J. , Hasenburg Annette , Markopoulos Christos , Dirix Luc , van de Velde Cornelis J.H. , Rea Daniel , Schnabel Catherine A. , Treuner Kai , Bayani Jane
Published: April 2024

Supplemental Figure 1. Continuous risk curves of BCI and BCIN+ for overall 10-year DR in patients who did not receive adjuvant chemotherapy.
A: risk of overall 10-year DR as a function of continuous BCI for N0 patients (N=1196); B: risk of overall 10-year DR as a function of continuous BCIN+ for N1 patients (N=1234); C: risk of overall 10-year DR as a function of continuous BCI for N0 HER2- patients (N=978); D: risk of overall 10-year DR as a function of continuous BCIN+ for N1 HER2- patients (N=1067).
Supplementary Table S6 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Authors: Dorff Tanya , Horvath Lisa G. , Autio Karen , Bernard-Tessier Alice , Rettig Matthew B. , Machiels Jean-Pascal , Bilen Mehmet A. , Lolkema Martijn P. , Adra Nabil , Rottey Sylvie , Greil Richard , Matsubara Nobuaki , Tan Daniel S.W. , Wong Alvin , Uemura Hiroji , Lemech Charlotte , Meran Johannes , Yu Youfei , Minocha Mukul , McComb Mason , Penny Hweixian Leong , Gupta Vinita , Hu Xuguang , Jurida Gabor , Kouros-Mehr Hosein , Janát-Amsbury Margit M. , Eggert Tobias , Tran Ben
Published: April 2024

Key medications used for the management of cytokine release syndrome
Supplementary Table S5 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Authors: Dorff Tanya , Horvath Lisa G. , Autio Karen , Bernard-Tessier Alice , Rettig Matthew B. , Machiels Jean-Pascal , Bilen Mehmet A. , Lolkema Martijn P. , Adra Nabil , Rottey Sylvie , Greil Richard , Matsubara Nobuaki , Tan Daniel S.W. , Wong Alvin , Uemura Hiroji , Lemech Charlotte , Meran Johannes , Yu Youfei , Minocha Mukul , McComb Mason , Penny Hweixian Leong , Gupta Vinita , Hu Xuguang , Jurida Gabor , Kouros-Mehr Hosein , Janát-Amsbury Margit M. , Eggert Tobias , Tran Ben
Published: April 2024

List of worst grade 4 treatment-emergent adverse events in dose exploration and dose expansion
Supplementary Table S1 from Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma
Authors: Habashy Karl J. , Dmello Crismita , Chen Li , Arrieta Victor A. , Kim Kwang-Soo , Gould Andrew , Youngblood Mark W. , Bouchoux Guillaume , Burdett Kirsten B. , Zhang Hui , Canney Michael , Stupp Roger , Sonabend Adam M.
Published: April 2024

Supplementary table 1. Genotype of glioma cell lines used.
Supplementary Table S2 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Authors: Dorff Tanya , Horvath Lisa G. , Autio Karen , Bernard-Tessier Alice , Rettig Matthew B. , Machiels Jean-Pascal , Bilen Mehmet A. , Lolkema Martijn P. , Adra Nabil , Rottey Sylvie , Greil Richard , Matsubara Nobuaki , Tan Daniel S.W. , Wong Alvin , Uemura Hiroji , Lemech Charlotte , Meran Johannes , Yu Youfei , Minocha Mukul , McComb Mason , Penny Hweixian Leong , Gupta Vinita , Hu Xuguang , Jurida Gabor , Kouros-Mehr Hosein , Janát-Amsbury Margit M. , Eggert Tobias , Tran Ben
Published: April 2024

Representativeness of study participants
Supplementary Figure S4 from Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma
Authors: Habashy Karl J. , Dmello Crismita , Chen Li , Arrieta Victor A. , Kim Kwang-Soo , Gould Andrew , Youngblood Mark W. , Bouchoux Guillaume , Burdett Kirsten B. , Zhang Hui , Canney Michael , Stupp Roger , Sonabend Adam M.
Published: April 2024

Supplementary Figure 4.  Paclitaxel and carboplatin combination lead to cell cycle arrest in the S and G2/M phases.
Results of flow cytometric analysis of synchronized GBM6 and MES83 cells that received PTX, CBDCA, or a combination of both drugs for 24 or 48 hours. On the right, we show the proportion of cells arrested at each of the SubG1, G0/G1, S, and G2/M phases.
Supplementary Figure S1 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Authors: Dorff Tanya , Horvath Lisa G. , Autio Karen , Bernard-Tessier Alice , Rettig Matthew B. , Machiels Jean-Pascal , Bilen Mehmet A. , Lolkema Martijn P. , Adra Nabil , Rottey Sylvie , Greil Richard , Matsubara Nobuaki , Tan Daniel S.W. , Wong Alvin , Uemura Hiroji , Lemech Charlotte , Meran Johannes , Yu Youfei , Minocha Mukul , McComb Mason , Penny Hweixian Leong , Gupta Vinita , Hu Xuguang , Jurida Gabor , Kouros-Mehr Hosein , Janát-Amsbury Margit M. , Eggert Tobias , Tran Ben
Published: April 2024

Study scheme
Supplementary Fig. S9 from Cooperative Armoring of CAR and TCR T Cells by T Cell–Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy
Authors: Nguyen Rosa , Doubrovina Ekaterina , Mousset Charlotte M. , Jin Benjamin Y. , Okada Reona , Zhang Xiyuan , Clavel Arina , Reyes-Gonzalez Jeyshka M. , Dyomin Vadim , Diaz Louis , Zhang Ling , Abbas Shahroze , Sun Ming , Hsieh Chao-Ming , Ho Mitchell , Shern Jack F. , Gulley James L. , Hinrichs Christian S.
Published: April 2024

Violin plots showing common marker expression by cluster.
Supplementary Fig. S5 from Cooperative Armoring of CAR and TCR T Cells by T Cell–Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy
Authors: Nguyen Rosa , Doubrovina Ekaterina , Mousset Charlotte M. , Jin Benjamin Y. , Okada Reona , Zhang Xiyuan , Clavel Arina , Reyes-Gonzalez Jeyshka M. , Dyomin Vadim , Diaz Louis , Zhang Ling , Abbas Shahroze , Sun Ming , Hsieh Chao-Ming , Ho Mitchell , Shern Jack F. , Gulley James L. , Hinrichs Christian S.
Published: April 2024

Growth kinetics of transduced T-cells following single-transduction with cytokine vector and IL-2 removal.
Supplementary Fig. S4 from Cooperative Armoring of CAR and TCR T Cells by T Cell–Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy
Authors: Nguyen Rosa , Doubrovina Ekaterina , Mousset Charlotte M. , Jin Benjamin Y. , Okada Reona , Zhang Xiyuan , Clavel Arina , Reyes-Gonzalez Jeyshka M. , Dyomin Vadim , Diaz Louis , Zhang Ling , Abbas Shahroze , Sun Ming , Hsieh Chao-Ming , Ho Mitchell , Shern Jack F. , Gulley James L. , Hinrichs Christian S.
Published: April 2024

In vitro shedding studies.
Supplementary Fig. S11 from Cooperative Armoring of CAR and TCR T Cells by T Cell–Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy
Authors: Nguyen Rosa , Doubrovina Ekaterina , Mousset Charlotte M. , Jin Benjamin Y. , Okada Reona , Zhang Xiyuan , Clavel Arina , Reyes-Gonzalez Jeyshka M. , Dyomin Vadim , Diaz Louis , Zhang Ling , Abbas Shahroze , Sun Ming , Hsieh Chao-Ming , Ho Mitchell , Shern Jack F. , Gulley James L. , Hinrichs Christian S.
Published: April 2024

Replicate in vivo adoptive TCR T-cell studies.
Supplementary Video 1 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Authors: Archer Sophie , Brailey Phillip M. , Song Minjung , Bartlett Phillip D. , Figueiredo Ines , Gurel Bora , Guo Christina , Brucklacher-Waldert Verena , Thompson H. Lorraine , Akinwale Jude , Boyle Samantha E. , Rossant Christine , Birkett Neil R. , Pizzey Julia , Maginn Mark , Legg James , Williams Richard , Johnston Colette M. , Bland-Ward Philip , de Bono Johann S. , Pierce Andrew J.
Published: April 2024

Supplementary Video 1
Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Authors: Archer Sophie , Brailey Phillip M. , Song Minjung , Bartlett Phillip D. , Figueiredo Ines , Gurel Bora , Guo Christina , Brucklacher-Waldert Verena , Thompson H. Lorraine , Akinwale Jude , Boyle Samantha E. , Rossant Christine , Birkett Neil R. , Pizzey Julia , Maginn Mark , Legg James , Williams Richard , Johnston Colette M. , Bland-Ward Philip , de Bono Johann S. , Pierce Andrew J.
Published: April 2024

Supplementary Figure 8: Spheroid end-of-study T=240h images
Supplementary Figure 7 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Authors: Archer Sophie , Brailey Phillip M. , Song Minjung , Bartlett Phillip D. , Figueiredo Ines , Gurel Bora , Guo Christina , Brucklacher-Waldert Verena , Thompson H. Lorraine , Akinwale Jude , Boyle Samantha E. , Rossant Christine , Birkett Neil R. , Pizzey Julia , Maginn Mark , Legg James , Williams Richard , Johnston Colette M. , Bland-Ward Philip , de Bono Johann S. , Pierce Andrew J.
Published: April 2024

Supplementary Figure 7: CRISPR-mediated PD-L1 gene knock-out in DU145-PSMA cells
Supplementary Figure 6 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Authors: Archer Sophie , Brailey Phillip M. , Song Minjung , Bartlett Phillip D. , Figueiredo Ines , Gurel Bora , Guo Christina , Brucklacher-Waldert Verena , Thompson H. Lorraine , Akinwale Jude , Boyle Samantha E. , Rossant Christine , Birkett Neil R. , Pizzey Julia , Maginn Mark , Legg James , Williams Richard , Johnston Colette M. , Bland-Ward Philip , de Bono Johann S. , Pierce Andrew J.
Published: April 2024

Supplementary Figure 6: Synergy quantitation for CB307 / pembrolizumab combination
Supplementary Table S3 from Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial
Authors: Oh Hyung-Joo , Bae Suk-Chul , Oh In-Jae , Park Cheol-Kyu , Jung Kyoung-Mi , Kim Da-Mi , Lee Jung-Won , Kang Chang Kyun , Park Il Yeong , Kim Young-Chul
Published: April 2024

Table S3. Comparison of adverse events between nicotinamide and placebo groups.
Supplementary Figure 11 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Authors: Archer Sophie , Brailey Phillip M. , Song Minjung , Bartlett Phillip D. , Figueiredo Ines , Gurel Bora , Guo Christina , Brucklacher-Waldert Verena , Thompson H. Lorraine , Akinwale Jude , Boyle Samantha E. , Rossant Christine , Birkett Neil R. , Pizzey Julia , Maginn Mark , Legg James , Williams Richard , Johnston Colette M. , Bland-Ward Philip , de Bono Johann S. , Pierce Andrew J.
Published: April 2024

Supplementary Figure 11: Vipivotide tetraxetan does not interfere with CB307 activity
Supplemental Methods 1 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Authors: Archer Sophie , Brailey Phillip M. , Song Minjung , Bartlett Phillip D. , Figueiredo Ines , Gurel Bora , Guo Christina , Brucklacher-Waldert Verena , Thompson H. Lorraine , Akinwale Jude , Boyle Samantha E. , Rossant Christine , Birkett Neil R. , Pizzey Julia , Maginn Mark , Legg James , Williams Richard , Johnston Colette M. , Bland-Ward Philip , de Bono Johann S. , Pierce Andrew J.
Published: April 2024

Supplemental Methods
Supplementary Figure S1 from Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial
Authors: Oh Hyung-Joo , Bae Suk-Chul , Oh In-Jae , Park Cheol-Kyu , Jung Kyoung-Mi , Kim Da-Mi , Lee Jung-Won , Kang Chang Kyun , Park Il Yeong , Kim Young-Chul
Published: April 2024

Figure S1. Effect of Nicotinamide on the expressions of RUNX1 and RUNX3 in urethaneinduced mouse lung cancers and human lung cancer cell lines
Supplementary Table S2 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization
Authors: Wang Haoran , Chen Yuping , Wang Xinshu , Huang Binhao , Xie Juntao , Yin Hui , Yang Jie , Wu Jinhuan , Yuan Jian , Zhang Jie
Published: April 2024

Supplementary Table S2. Molecular characteristics of HRR mutations in MPML patients.
Supplementary Figure S2 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization
Authors: Wang Haoran , Chen Yuping , Wang Xinshu , Huang Binhao , Xie Juntao , Yin Hui , Yang Jie , Wu Jinhuan , Yuan Jian , Zhang Jie
Published: April 2024

Supplementary Figure S2: The expression of four HJR genes in human lung cancer cells.
Supplementary Figure S1 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization
Authors: Wang Haoran , Chen Yuping , Wang Xinshu , Huang Binhao , Xie Juntao , Yin Hui , Yang Jie , Wu Jinhuan , Yuan Jian , Zhang Jie
Published: April 2024

Supplementary Figure S1: The workflow of this study.
Supplementary Table S5 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Authors: Gitto Sarah B. , Whicker Margaret , Davies Gareth , Kumar Sushil , Kinneer Krista , Xu Haineng , Lewis Arthur , Mamidi Srinivas , Medvedev Sergey , Kim Hyoung , Anderton Judith , Tang E. Jessica , Ferman Benjamin , Coats Steven , Wilkinson Robert W. , Brown Eric , Powell Daniel J. , Simpkins Fiona
Published: April 2024

Western blot primary antibodies and dilution.
Supplementary Table S3 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Authors: Gitto Sarah B. , Whicker Margaret , Davies Gareth , Kumar Sushil , Kinneer Krista , Xu Haineng , Lewis Arthur , Mamidi Srinivas , Medvedev Sergey , Kim Hyoung , Anderton Judith , Tang E. Jessica , Ferman Benjamin , Coats Steven , Wilkinson Robert W. , Brown Eric , Powell Daniel J. , Simpkins Fiona
Published: April 2024

IHC analysis of human ovarian cancer tumors and subject information.
Supplementary Figure S4 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Authors: Gitto Sarah B. , Whicker Margaret , Davies Gareth , Kumar Sushil , Kinneer Krista , Xu Haineng , Lewis Arthur , Mamidi Srinivas , Medvedev Sergey , Kim Hyoung , Anderton Judith , Tang E. Jessica , Ferman Benjamin , Coats Steven , Wilkinson Robert W. , Brown Eric , Powell Daniel J. , Simpkins Fiona
Published: April 2024

Statistical summary of B7-H4-ADC activity in xenograft models and activity in breast cancer PDX models.
Supplementary Figure S3 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Authors: Gitto Sarah B. , Whicker Margaret , Davies Gareth , Kumar Sushil , Kinneer Krista , Xu Haineng , Lewis Arthur , Mamidi Srinivas , Medvedev Sergey , Kim Hyoung , Anderton Judith , Tang E. Jessica , Ferman Benjamin , Coats Steven , Wilkinson Robert W. , Brown Eric , Powell Daniel J. , Simpkins Fiona
Published: April 2024

Western blot analysis of B7-H4-ADC activation of DNA-response pathway.
Supplementary Table 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
Authors: Singh Harshabad , Sahgal Pranshu , Kapner Kevin , Corsello Steven M. , Gupta Hersh , Gujrathi Rahul , Li Yvonne Y. , Cherniack Andrew D. , El Alam Raquelle , Kerfoot Joseph , Andrews Elizabeth , Lee Annette , Nambiar Chetan , Hannigan Alison M. , Remland Joshua , Brais Lauren , Leahy Meghan E. , Rubinson Douglas A. , Schlechter Benjamin L. , Meyerson Matthew , Kuang Yanan , Paweletz Cloud P. , Lee Jessica K. , Quintanilha Julia C.F. , Aguirre Andrew J. , Perez Kimberly J. , Huffman Brandon M. , Rossi Humberto , Abrams Thomas A. , Kabraji Sheheryar , Trusolino Livio , Bertotti Andrea , Sicinska Ewa T. , Parikh Aparna R. , Wolpin Brian M. , Schrock Alexa B. , Giannakis Marios , Ng Kimmie , Meyerhardt Jeffrey A. , Hornick Jason L. , Sethi Nilay S. , Cleary James M.
Published: April 2024

Supplementary Table 4. Impact of clinical, genomic features on time to treatment discontinuation for HER2 directed therapy in the FH-FMI CGDB.
Supplementary Figure S12 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Authors: Gitto Sarah B. , Whicker Margaret , Davies Gareth , Kumar Sushil , Kinneer Krista , Xu Haineng , Lewis Arthur , Mamidi Srinivas , Medvedev Sergey , Kim Hyoung , Anderton Judith , Tang E. Jessica , Ferman Benjamin , Coats Steven , Wilkinson Robert W. , Brown Eric , Powell Daniel J. , Simpkins Fiona
Published: April 2024

Immunohistochemical analysis of PDX tumors for Ki67 after ADC treatment.
Supplementary Figure S1 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Authors: Gitto Sarah B. , Whicker Margaret , Davies Gareth , Kumar Sushil , Kinneer Krista , Xu Haineng , Lewis Arthur , Mamidi Srinivas , Medvedev Sergey , Kim Hyoung , Anderton Judith , Tang E. Jessica , Ferman Benjamin , Coats Steven , Wilkinson Robert W. , Brown Eric , Powell Daniel J. , Simpkins Fiona
Published: April 2024

Representative B7-H4 immunohistochemistry.
Supplementary Tables from A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions
Authors: Küçükosmanoglu Asli , Scoarta Silvia , Houweling Megan , Spinu Nicoleta , Wijnands Thomas , Geerdink Niek , Meskers Carolien , Kanev Georgi K. , Kiewiet Bert , Kouwenhoven Mathilde , Noske David , Wurdinger Tom , Pouwer Marianne , Wolff Mark , Westerman Bart A.
Published: April 2024

Supplementary Tables
Supplementary Figure 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
Authors: Singh Harshabad , Sahgal Pranshu , Kapner Kevin , Corsello Steven M. , Gupta Hersh , Gujrathi Rahul , Li Yvonne Y. , Cherniack Andrew D. , El Alam Raquelle , Kerfoot Joseph , Andrews Elizabeth , Lee Annette , Nambiar Chetan , Hannigan Alison M. , Remland Joshua , Brais Lauren , Leahy Meghan E. , Rubinson Douglas A. , Schlechter Benjamin L. , Meyerson Matthew , Kuang Yanan , Paweletz Cloud P. , Lee Jessica K. , Quintanilha Julia C.F. , Aguirre Andrew J. , Perez Kimberly J. , Huffman Brandon M. , Rossi Humberto , Abrams Thomas A. , Kabraji Sheheryar , Trusolino Livio , Bertotti Andrea , Sicinska Ewa T. , Parikh Aparna R. , Wolpin Brian M. , Schrock Alexa B. , Giannakis Marios , Ng Kimmie , Meyerhardt Jeffrey A. , Hornick Jason L. , Sethi Nilay S. , Cleary James M.
Published: April 2024

Supplementary Figure 4. RAS/RAF co-altered, HER2 amplified CRC reflects a unique genomic subset with HER2 intratumoral heterogeneity.
Supplementary Figure 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
Authors: Singh Harshabad , Sahgal Pranshu , Kapner Kevin , Corsello Steven M. , Gupta Hersh , Gujrathi Rahul , Li Yvonne Y. , Cherniack Andrew D. , El Alam Raquelle , Kerfoot Joseph , Andrews Elizabeth , Lee Annette , Nambiar Chetan , Hannigan Alison M. , Remland Joshua , Brais Lauren , Leahy Meghan E. , Rubinson Douglas A. , Schlechter Benjamin L. , Meyerson Matthew , Kuang Yanan , Paweletz Cloud P. , Lee Jessica K. , Quintanilha Julia C.F. , Aguirre Andrew J. , Perez Kimberly J. , Huffman Brandon M. , Rossi Humberto , Abrams Thomas A. , Kabraji Sheheryar , Trusolino Livio , Bertotti Andrea , Sicinska Ewa T. , Parikh Aparna R. , Wolpin Brian M. , Schrock Alexa B. , Giannakis Marios , Ng Kimmie , Meyerhardt Jeffrey A. , Hornick Jason L. , Sethi Nilay S. , Cleary James M.
Published: April 2024

Supplementary Figure 1. Cohort identification.
Supplementary Table S3 from Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Authors: Lou Hanmei , Cai Hongbing , Huang Xin , Li Guiling , Wang Li , Liu Fei , Qin Wenjing , Liu Ting , Liu Wei , Wang Zhongmin Maxwell , Li Baiyong , Xia Yu , Wang Jing
Published: April 2024

Supplementary Table S3. Representativeness of Study Participants.
Supplementary Table S1 from Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Authors: Lou Hanmei , Cai Hongbing , Huang Xin , Li Guiling , Wang Li , Liu Fei , Qin Wenjing , Liu Ting , Liu Wei , Wang Zhongmin Maxwell , Li Baiyong , Xia Yu , Wang Jing
Published: April 2024

Supplementary Table S1. Summary of treatment-related serious adverse events.
Figure 1 from Noninvasive Stratification of Colon Cancer by Multiplex PET Imaging
Authors: Malviya Gaurav , Lannagan Tamsin R.M. , Johnson Emma , Mackintosh Agata , Bielik Robert , Peters Adam , Soloviev Dmitry , Brown Gavin , Jackstadt Rene , Nixon Colin , Gilroy Kathryn , Campbell Andrew , Sansom Owen J. , Lewis David Y.
Published: April 2024

Colon cancer models have genotypic and phenotypic diversity. A, The alleles in the GEMM used in this study. Cre, Cre recombinase; ER, estrogen receptor; loxP, Cre-loxP recombination site. B, Oncoprint showing the prevalence of genetic alterations of the alleles in A, determined using cBioportal from the Colorectal Adenocarcinoma, TCGA, PanCancer Atlas (n = 524). C, Venn diagrams of the genetic crossing strategies for the GEMM. D, Heatmap illustrating correlation of intestinal cancer GEMM gene expression with patient-derived CMS profiles. E, Gene set enrichment analysis for the GEMM with the Molecular Signatures Database (MSigDB) hallmark gene set. Data were ordered using hierarchal clustering. Extended heatmap is shown in Supplementary Fig. S1. (A, Created with BioRender.com.)
Supplementary Figure S1 from Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Authors: Lou Hanmei , Cai Hongbing , Huang Xin , Li Guiling , Wang Li , Liu Fei , Qin Wenjing , Liu Ting , Liu Wei , Wang Zhongmin Maxwell , Li Baiyong , Xia Yu , Wang Jing
Published: April 2024

Supplementary Figure S1. The typical computed tomography scans of patients.
Supplementary Table S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Authors: Peters Solange , Angevin Eric , Alonso-Gordoa Teresa , Rohrberg Kristoffer , Melero Ignacio , Mellado Begoña , Perez-Gracia Jose-Luis , Tabernero Josep , Adessi Celine , Boetsch Christophe , Watson Carl , Dal Porto Joseph , Dejardin David , Del Nagro Christopher , Nicolini Valeria , Evers Stefan , Klein Christian , Leutgeb Barbara , Pisa Pavel , Rossmann Eva , Saro José , Umana Pablo , Charo Jehad , Teichgräber Volker , Steeghs Neeltje
Published: April 2024

Supplementary Table S2. Study representation of underserved communities.
Supplementary Table 7 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Authors: Parra Edwin Roger , Zhang Jiexin , Duose Dzifa Yawa , Gonzalez-Kozlova Edgar , Redman Mary W. , Chen Hong , Manyam Ganiraju C. , Kumar Gayatri , Zhang Jianhua , Song Xingzhi , Lazcano Rossana , Marques-Piubelli Mario L. , Laberiano-Fernandez Caddie , Rojas Frank , Zhang Baili , Taing Len , Jhaveri Aashna , Geisberg Jacob , Altreuter Jennifer , Michor Franziska , Provencher James , Yu Joyce , Cerami Ethan , Moravec Radim , Kannan Kasthuri , Luthra Rajyalakshmi , Alatrash Gheath , Huang Hsin-Hui , Xie Hui , Patel Manishkumar , Nie Kai , Harris Jocelyn , Argueta Kimberly , Lindsay James , Biswas Roshni , Van Nostrand Stephen , Kim-Schulze Seunghee , Gray Jhanelle E. , Herbst Roy S. , Wistuba Ignacio I. , Gettinger Scott , Kelly Karen , Bazhenova Lyudmila , Gnjatic Sacha , Lee J. Jack , Zhang Jianjun , Haymaker Cara
Published: April 2024

Supplementary Table 7. Comparation of median densities between patients who experienced exceptional responses and early progression/death according to compartment.
Supplementary Methods S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Authors: Peters Solange , Angevin Eric , Alonso-Gordoa Teresa , Rohrberg Kristoffer , Melero Ignacio , Mellado Begoña , Perez-Gracia Jose-Luis , Tabernero Josep , Adessi Celine , Boetsch Christophe , Watson Carl , Dal Porto Joseph , Dejardin David , Del Nagro Christopher , Nicolini Valeria , Evers Stefan , Klein Christian , Leutgeb Barbara , Pisa Pavel , Rossmann Eva , Saro José , Umana Pablo , Charo Jehad , Teichgräber Volker , Steeghs Neeltje
Published: April 2024

Supplementary Methods
Supplementary Table 6 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Authors: Parra Edwin Roger , Zhang Jiexin , Duose Dzifa Yawa , Gonzalez-Kozlova Edgar , Redman Mary W. , Chen Hong , Manyam Ganiraju C. , Kumar Gayatri , Zhang Jianhua , Song Xingzhi , Lazcano Rossana , Marques-Piubelli Mario L. , Laberiano-Fernandez Caddie , Rojas Frank , Zhang Baili , Taing Len , Jhaveri Aashna , Geisberg Jacob , Altreuter Jennifer , Michor Franziska , Provencher James , Yu Joyce , Cerami Ethan , Moravec Radim , Kannan Kasthuri , Luthra Rajyalakshmi , Alatrash Gheath , Huang Hsin-Hui , Xie Hui , Patel Manishkumar , Nie Kai , Harris Jocelyn , Argueta Kimberly , Lindsay James , Biswas Roshni , Van Nostrand Stephen , Kim-Schulze Seunghee , Gray Jhanelle E. , Herbst Roy S. , Wistuba Ignacio I. , Gettinger Scott , Kelly Karen , Bazhenova Lyudmila , Gnjatic Sacha , Lee J. Jack , Zhang Jianjun , Haymaker Cara
Published: April 2024

Supplementary Table 6. Associations of genes with outcomes in both arms.
Supplementary Figure S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Authors: Peters Solange , Angevin Eric , Alonso-Gordoa Teresa , Rohrberg Kristoffer , Melero Ignacio , Mellado Begoña , Perez-Gracia Jose-Luis , Tabernero Josep , Adessi Celine , Boetsch Christophe , Watson Carl , Dal Porto Joseph , Dejardin David , Del Nagro Christopher , Nicolini Valeria , Evers Stefan , Klein Christian , Leutgeb Barbara , Pisa Pavel , Rossmann Eva , Saro José , Umana Pablo , Charo Jehad , Teichgräber Volker , Steeghs Neeltje
Published: April 2024

Supplementary Figure S1. The effect of obinutuzumab pretreatment on A, De-novo vaccination with tetanus toxoid
and B, Memory re-call to immune rechallenge with a measles/rubella vaccination in cynomolgus monkeys.
Supplementary Video S2 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Authors: Wolf Steven P. , Anastasopoulou Vasiliki , Drousch Kimberley , Diehl Markus I. , Engels Boris , Yew Poh Yin , Kiyotani Kazuma , Nakamura Yusuke , Schreiber Karin , Schreiber Hans , Leisegang Matthias
Published: April 2024

Supplementary Video S2
Supplementary Video S1 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Authors: Wolf Steven P. , Anastasopoulou Vasiliki , Drousch Kimberley , Diehl Markus I. , Engels Boris , Yew Poh Yin , Kiyotani Kazuma , Nakamura Yusuke , Schreiber Karin , Schreiber Hans , Leisegang Matthias
Published: April 2024

Supplementary Video S1
Supplementary Figure 5 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Authors: Parra Edwin Roger , Zhang Jiexin , Duose Dzifa Yawa , Gonzalez-Kozlova Edgar , Redman Mary W. , Chen Hong , Manyam Ganiraju C. , Kumar Gayatri , Zhang Jianhua , Song Xingzhi , Lazcano Rossana , Marques-Piubelli Mario L. , Laberiano-Fernandez Caddie , Rojas Frank , Zhang Baili , Taing Len , Jhaveri Aashna , Geisberg Jacob , Altreuter Jennifer , Michor Franziska , Provencher James , Yu Joyce , Cerami Ethan , Moravec Radim , Kannan Kasthuri , Luthra Rajyalakshmi , Alatrash Gheath , Huang Hsin-Hui , Xie Hui , Patel Manishkumar , Nie Kai , Harris Jocelyn , Argueta Kimberly , Lindsay James , Biswas Roshni , Van Nostrand Stephen , Kim-Schulze Seunghee , Gray Jhanelle E. , Herbst Roy S. , Wistuba Ignacio I. , Gettinger Scott , Kelly Karen , Bazhenova Lyudmila , Gnjatic Sacha , Lee J. Jack , Zhang Jianjun , Haymaker Cara
Published: April 2024

Supplementary Figure 5. Gene mutation profiles.